CNS/Neurology

This technology is a conditional human ALFY protein-expressing mouse model for the study of diseases driven by pathological protein aggregation in the nervous system.

This technology is a mouse model engineered to conditionally delete the autophagy-linked FYVE protein WDFY3, creating an effective research tool for studying autophagy, mitophagy, efferocytosis, and diseases impacted by these pathways, including neurodevelopmental and neurodegenerative disorders.

This technology identifies several pathogenic roles for Delta-2-tubulin (D2) in chemotherapy-induced peripheral neuropathy that can be used as a therapeutic target.

Quantitative measurement of eye and head movements for the diagnosis of traumatic brain injury and neurodegeneration.

This technology is a nucleotide sequence for amplifying the expression of WDFY3 gene or its encoded protein, Autophagy-Linked FYVE (ALFY), that can be used to promote protein aggregate clearance in neurodegenerative diseases.

This technology proposes to modulate mitofusin-regulated microtubule acetylation for the treatment of peripheral neuropathy.

This technology is a method to treat Alzheimer’s disease by reducing the level of the cellular biomarker APP-C99.

This technology is a mechanism for treating brain disorders resulting from Group A Streptococcus infection including encephalitis by targeting a serum cytokine biomarker IL-17A.

This technology is NeuroScore AI, an automated AI program that can be used to calculate Alzheimer’s Disease risk score by transcribing audio files from standardized cognitive testing.

This technology is a hybrid configuration of multi-coils and radiofrequency magnets that can improve clinical magnetic resonance imaging (MRI) quality.

This technology is a dual-head MRI system equipped with local shimming capabilities for simultaneous functional imaging of two adjacent subjects, facilitating the study of interpersonal interactions and social connections.

This technology is a method of using metabolic profiling-related biomarkers to identify newborns or infants with autism spectrum disorder for early intervention.

This technology is an in vivo tool using focused ultrasound (FUS) with microbubbles to induce blood-brain barrier opening (BBBO) and increase serum extracellular vesicle (EV) levels.

This technology includes two chemical compounds that are phosphodiesterase type 5 (PDE5) inhibitors with a benzonaphthyridine derivative chemical scaffold that has not previously been used to treat Alzheimer’s disease or other conditions involving phosphodiesterase PDE5 function.

This technology uses peptides secreted by engineered bacteria to reduce virulence of Fusobacterium nucleatum.